These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27918164)

  • 1. [The possibility of using progesterone receptor modulators in the treatment of myomas].
    Šimetka O; Klát J; Bajsová S
    Ceska Gynekol; 2016; 81(6):452-457. PubMed ID: 27918164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The use of selective progesterone receptor modulators in the treatment of myomas].
    Šimetka O; Klát J
    Ceska Gynekol; 2016; 81(4):317-320. PubMed ID: 27882756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?
    Donnez J; Donnez O; Dolmans MM
    Fertil Steril; 2014 Sep; 102(3):640-8. PubMed ID: 25106762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators.
    Donnez J; Arriagada P; Donnez O; Dolmans MM
    Curr Opin Obstet Gynecol; 2015 Dec; 27(6):422-31. PubMed ID: 26536207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
    Donnez J; Donnez O; Dolmans MM
    Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
    Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
    Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
    [No Abstract]   [Full Text] [Related]  

  • 7. Ulipristal acetate for uterine fibroid-related symptoms.
    Puchar A; Luton D; Koskas M
    Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
    Talaulikar VS; Manyonda I
    Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study.
    Bizzarri N; Ghirardi V; Remorgida V; Venturini PL; Ferrero S
    Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():22-6. PubMed ID: 26142912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ulipristal acetate and SPRM: A new entity for the therapeutic strategy for symptomatic myomas].
    Fernandez H
    Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):671-672. PubMed ID: 30293948
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.
    Rabe T; Saenger N; Ebert AD; Roemer T; Tinneberg HR; De Wilde RL; Wallwiener M
    Biomed Res Int; 2018; 2018():1374821. PubMed ID: 30539001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
    Singh SS; Belland L; Leyland N; von Riedemann S; Murji A
    Am J Obstet Gynecol; 2018 Jun; 218(6):563-572.e1. PubMed ID: 29274830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The place of selective progesterone receptor modulators in myoma therapy.
    Donnez J; Donnez O; Courtoy GE; Dolmans MM
    Minerva Ginecol; 2016 Jun; 68(3):313-20. PubMed ID: 26930390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ulipristal acetate, 5mg: a new alternative].
    Monleón Sancho J; Romaguera E; Romero A; Higueras G; Morcillo I; Fuster S
    Med Clin (Barc); 2013 Jul; 141 Suppl 1():40-6. PubMed ID: 24314567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
    Brazert M; Korman MP; Pawelczyk LA
    Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.
    Rozenberg S; Praet J; Pazzaglia E; Gilles C; Manigart Y; Vandromme J
    Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):393-399. PubMed ID: 28567743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging treatment options for uterine fibroids.
    Donnez J; Arriagada P; Donnez O; Dolmans MM
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):17-23. PubMed ID: 29486606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
    Szamatowicz M; Kotarski J
    Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.
    Palaia I; Del Negro V; Fracassi A; Schiavi M; Di Donato V; Fischetti M; Muzii L; Benedetti Panici P
    Gynecol Endocrinol; 2020 Jul; 36(7):660-661. PubMed ID: 31878806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ulipristal acetate versus placebo for fibroid treatment before surgery.
    Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
    N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.